title: Antihyperalgesic activity of the methanol extract and some constituents obtained from Polygala cyparissias (Polygalaceae).
abstract: Polygala cyparissias, used in folk medicine as an anaesthetic, has already demonstrated antinociceptive activity against acute pain. In this study, we investigated the antihyperalgesic activity of the P. cyparissias methanol extract (PCME) from which the following compounds were isolated: α-spinasterol (PC1), 1,3-dihydroxy-7-methoxyxanthone (PC2), 1,7-dihydroxy-2,3-methylenedioxyxanthone (PC3) and 1,3,6,8-tetrahydroxy-2,7-dimethoxyxanthone (PC4). The antihyperalgesic effect was evaluated using experimental models of persistent pain induced by carrageenan, lipopolysaccharide (LPS), Freund's Complete Adjuvant (CFA), PGE(2) or epinephrine. The partial ligation of the sciatic nerve (PLSN) model was also used. In inflammatory hyperalgesia induced by carrageenan, LPS, CFA or PGE(2), the inhibition values obtained with the PCME treatment were 68 ± 3%, 89 ± 5%, 43 ± 3% and 40 ± 4%, respectively. In epinephrine-induced hyperalgesia, the extract was effective, reducing 99 ± 11% of response frequency, while in PLSN, 54 ± 4% of inhibition was obtained. These results allow to suggest that the antihyperalgesic activity of PCME is, at least in part, related to its capability to inhibit the hypersensitization induced by pro-inflammatory mediators, such as LPS, carrageenan and CFA, without interfering with locomotor activity or motor performance. Furthermore, compounds PC1, PC3 and PC4 inhibited the carrageenan-induced hyperalgesia with inhibition of 42 ± 6%, 48 ± 5% and 64 ± 4%, respectively. In summary, our data demonstrate that PCME has relevant antihyperalgesic activity and that the isolated PC1, PC3 and PC4 seem to be responsible, at least in part, for this important effect.
authors.affiliation: Programa de Pós-Graduação em Ciências Farmacêuticas, Núcleo de Investigações Químico-Farmacêuticas, Universidade do Vale do Itajaí-UNIVALI, Itajaí, Santa Catarina, Brazil.
authors.forename: Luiz C
authors.initials: LC
authors.lastname: Klein-Júnior
authors.forename: Nicole A
authors.initials: NA
authors.lastname: Meira
authors.forename: Tania M B
authors.initials: TM
authors.lastname: Bresolin
authors.forename: Valdir
authors.initials: V
authors.lastname: Cechinel-Filho
authors.forename: Nara L M
authors.initials: NL
authors.lastname: Quintão
mesh_terms: D000700:Analgesics / Q000302:isolation & purification / Q000494:pharmacology*; D000818:Animals; D002351:Carrageenan / Q000009:adverse effects; D004195:Disease Models, Animal; D004353:Drug Evaluation, Preclinical; D004837:Epinephrine / Q000009:adverse effects; D005260:Female; D005620:Freund's Adjuvant / Q000009:adverse effects; D006930:Hyperalgesia / Q000139:chemically induced / Q000188:drug therapy*; D007249:Inflammation / Q000139:chemically induced / Q000188:drug therapy; D008070:Lipopolysaccharides / Q000009:adverse effects; D008519:Medicine, Traditional; D000432:Methanol; D051379:Mice; D009437:Neuralgia / Q000188:drug therapy; D010146:Pain / Q000188:drug therapy; D010936:Plant Extracts / Q000494:pharmacology*; D031801:Polygala / Q000737:chemistry*; D012584:Sciatic Nerve / Q000187:drug effects; D013265:Stigmasterol / Q000031:analogs & derivatives / Q000302:isolation & purification / Q000494:pharmacology; D044004:Xanthones / Q000302:isolation & purification / Q000494:pharmacology
chemical_list: C576943:1,3,6,8-tetrahydroxy-2,7-dimethoxyxanthone; C525295:1,6-dihydroxy-7,8-dimethoxy-2,3-methylenedioxyxanthone; D000700:Analgesics; D008070:Lipopolysaccharides; D010936:Plant Extracts; D044004:Xanthones; C031312:spinasterol; C018087:isogentisin; D002351:Carrageenan; D005620:Freund's Adjuvant; D013265:Stigmasterol; D000432:Methanol; D004837:Epinephrine